Monitoring glaucoma at home

November 20, 2020

Glaucoma is a chronic condition that affects cells at the back of the eye. It is the leading cause of irreversible blindness worldwide, and is responsible for 1 in 10 cases of serious sight impairment in the UK.

People with glaucoma, or at risk of developing glaucoma, require lifelong monitoring, including regular eye tests to track the progression of the disease. Currently, these examinations require regular hospital visits (e.g., twice yearly, for life) and use expensive, specialist equipment.

Aging populations make this hospital-only model of patient-management unsustainable, and many clinics are already overstretched, with appointments routinely delayed or cancelled. In the UK today,
This situation has been compounded by the COVID-19 pandemic, since the inability to sanitise equipment between use has led to all routine sight assessments being suspended in the UK. The long-term effects of this are unknown, but experts suggest that further increases in appointment delays and avoidable blindness appear inevitable.

Even if routine assessments are ever fully resumed, it is also thought that the current system of annual hospital visits is insufficient to track the most aggressive forms of glaucoma. Multiple studies have already suggested that more frequent (e.g., monthly) glaucoma eye tests could substantially improve clinical outcomes: allowing high risk patients to be treated sooner and more appropriately.


The research involved 20 NHS glaucoma patients from across England and Wales who were provided with a prototype, tablet-based eye test ('Eyecatcher') for six months. Using the device, they were asked to run the home glaucoma eye test themselves, testing each of their eyes once a month.

Similar to conventional eye tests for glaucoma, patients looked at a central cross presented on the device, and pressed a button when they saw a flash of light, which appeared at different locations and was of variable intensity. The computer's front-facing camera also recorded them during the test, and artificial intelligence (AI) was used to perform facial recognition and head-/eye-tracking, to ensure people performed the test correctly.

Accuracy was assessed by comparing measurements made at home to conventional 'gold standard' assessments performed in clinic at both the start and end of the study. Adherence was quantified as the percentage of tests completed.

The study found that 98% of home tests were completed successfully (high adherence), and that the data from the home-monitoring tests were in strong agreement with the gold standard clinical assessments (high accuracy).

The use of home-monitoring data was also shown to reduce measurement error when combined with current clinical data (by over 50% in 90% of eyes). This could potentially allow cases of rapid sight loss to be detected months or even years earlier.

This is the first study in the world that suggests glaucoma eye tests can be performed accurately at home by patients themselves.

Future studies will examine whether home-monitoring is sustainable over longer periods, and is capable of detecting rapidly progressing cases of glaucoma.

The study authors are also preparing a follow-up study that will present the views and opinions of people with glaucoma, regarding home-monitoring.

"This is tremendously exciting news. Effective home-monitoring would be a win-win-win for patients, clinicians, and the taxpayer alike, and it looks like the technology finally exists to make it a reality. This news is particularly timely, since home-monitoring is just one of the ways we can help make the NHS more resilient and sustainable, post-COVID."
The study was funded by Glaucoma UK, the College of Optometrists, and Fight for Sight UK, and is
American Journal of Ophthalmology.


City University London

Related Glaucoma Articles from Brightsurf:

Monitoring glaucoma at home
Glaucoma is a chronic condition that affects cells at the back of the eye.

Study finds novel mechanism that may confer protection against glaucoma
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.

AI-supported test for very early signs of glaucoma progression
A new test can detect glaucoma progression 18 months earlier than the current gold standard method, according to results from a UCL-sponsored clinical trial.

New method gives glaucoma researchers control over eye pressure
Neuroscientists have developed a new method that permits continuous regulation of eye pressure without damage, becoming the first to definitively prove pressure in the eye is sufficient to cause and explain glaucoma.

Glaucoma care in prison inmates
Data fromĀ 82 prison inmates treated in a glaucoma clinic at an academic hospital were used in this observational study to report on how treatment and follow-up, including medication adherence, were are managed.

New glaucoma test to help prevent blindness
Researchers have identified 107 genes that increase a person's risk of developing the eye disease glaucoma, and now developed a genetic test to detect those at risk of going blind from it.

Air pollution linked to higher glaucoma risk
Living in a more polluted area is associated with a greater likelihood of having glaucoma, a debilitating eye condition that can cause blindness, finds a new UCL-led study in the UK.

Long-term statin use associated with lower glaucoma risk
A new study brings the connection between statin use and risk of glaucoma into sharper focus.

Health burden of glaucoma has risen worldwide
The health burden of glaucoma has continuously increased around the globe in the past 25 years, according to an Acta Opthalmologica study.

UAlberta scientists first to pinpoint a cause of pigmentary glaucoma
An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition.

Read More: Glaucoma News and Glaucoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to